Combination therapy outperforms chemotherapy in patients with chronic lymphocytic leukaemia Chemotherapy has been the most effective treatment to date for young and fit patients with chronic lymphocytic leukaemia (CLL). The disease is the most common form of leukaemia in the Western world, causing a substantial health burden on patients and society. It is currently incurable. Research led by researchers from Cologne University, Amsterdam UMC and Copenhagen University, now shows that a chemofree drug-combination therapy is more effective and produces fewer side effects. The results of this study are published today in the New England Journal of Medicine.
The Methotrexate Monitoring trialRenske Hebing was awarded the AII Extension Grant in 2021 for her research proposal “Pharmacokinetics of Oral and Subcutaneous Methotrexate in Red and White Blood Cells in Patients with Early Rheumatoid Arthritis – the Methotrexate Monitoring Trial (MeMo study)”. Recently, Renske’s article was published in the Annals of the Rheumatic Diseases (ARD).
Grant awarded: clinical trial anti-inflammatory drug for Sjögren's syndromeA grant of 200,000 euros has been awarded to Dr. Derk Jan Jager and colleagues to set up a study on the safety and efficacy of a drug (AZD9056) for patients with Sjögren’s syndrome. This study will examine whether the drug is able to preserve the function of the salivary glands in patients with Sjögren's syndrome.
Reviewing the Alzheimer’s drug development landscapePieter van Bokhoven and colleagues looked into the landscape of the Alzheimer’s disease drug development. This review gives insight into the status of AD drug development by comparing drugs in preclinical development to drugs currently tested in clinical trials.